FHIR © HL7.org  |  FHIRsmith 0.16.0  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Packagede.medizininformatikinitiative.kerndatensatz.molgen
Resource TypeObservation
IdObservation-mii-exa-molgen-therapeutische-implikation-1.json
FHIR VersionR4

Resources that use this resource

No resources found


Resources that this resource uses

No resources found


Narrative

Note: links and images are rebased to the (stated) source


English


Generated Narrative: Observation mii-exa-molgen-therapeutische-implikation-1

Profiles: MII PR MolGen Therapeutische Implikation version: 2027.0.0-ballot.1, Therapeutic Implication version: 3.0.0

status: Final

category: Laboratory, Genetics

code: Therapeutic Implication

subject: Maja Julia Van-der-Dussen (official) Female, DoB: 1968-09-19 ( Medical record number (use: usual, ))

effective: 2022-04-07

performer: Practitioner Dr. Daniel Schmidt(official)

derivedFrom: Observation Genetic variant assessment

component

code: Conclusion Text

value: Nachweis einer aktivierenden Mutation BRAF V600E. Triple-Therapie mit einem EGFR-Antikörper sowie einem BRAF- und einem MEK- Inhibitor prüfen.

component

code: Medication assessed [ID]

value: BRAF Inhibitor

component

code: Medication assessed [ID]

value: EGFR (Epidermal Growth Factor Receptor) inhibitors

component

code: Medication assessed [ID]

value: Mitogen-activated protein kinase (MEK) inhibitors


German


Generated Narrative: Observation mii-exa-molgen-therapeutische-implikation-1

Profiles: MII PR MolGen Therapeutische Implikation version: 2027.0.0-ballot.1, Therapeutic Implication version: 3.0.0

status: Final

category: Laboratory, Genetik

code: Therapeutic Implication

subject: Maja Julia Van-der-Dussen (official) Female, DoB: 1968-09-19 ( Krankenaktennummer (use: usual, ))

effective: 2022-04-07

performer: Practitioner Dr. Daniel Schmidt(official)

derivedFrom: Observation Genetic variant assessment

component

code: Conclusion Text

value: Nachweis einer aktivierenden Mutation BRAF V600E. Triple-Therapie mit einem EGFR-Antikörper sowie einem BRAF- und einem MEK- Inhibitor prüfen.

component

code: Medication assessed [ID]

value: BRAF Inhibitor

component

code: Medication assessed [ID]

value: EGFR (Epidermal Growth Factor Receptor) inhibitors

component

code: Medication assessed [ID]

value: Mitogen-activated protein kinase (MEK) inhibitors


Source1

{
  "resourceType": "Observation",
  "id": "mii-exa-molgen-therapeutische-implikation-1",
  "meta": {
    "profile": [
      "https://www.medizininformatik-initiative.de/fhir/ext/modul-molgen/StructureDefinition/therapeutische-implikation|2027.0.0-ballot.1",
      "http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/therapeutic-implication|3.0.0"
    ]
  },
  "text": {
    "status": "generated",
    "div": "<!-- snip (see above) -->"
  },
  "status": "final",
  "category": [
    {
      "coding": [
        {
          "system": "http://terminology.hl7.org/CodeSystem/observation-category",
          "code": "laboratory",
          "display": "Laboratory"
        }
      ]
    },
    {
      "coding": [
        {
          "system": "http://terminology.hl7.org/CodeSystem/v2-0074",
          "code": "GE"
        }
      ]
    }
  ],
  "code": {
    "coding": [
      {
        "system": "http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs",
        "code": "therapeutic-implication",
        "display": "Therapeutic Implication"
      }
    ]
  },
  "subject": {
    "reference": "Patient/mii-exa-molgen-patient"
  },
  "effectiveDateTime": "2022-04-07",
  "performer": [
    {
      "reference": "Practitioner/mii-exa-molgen-practitioner-lab"
    }
  ],
  "derivedFrom": [
    {
      "reference": "Observation/mii-exa-molgen-variante-1"
    }
  ],
  "component": [
    {
      "code": {
        "coding": [
          {
            "system": "http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs",
            "code": "conclusion-string"
          }
        ]
      },
      "valueString": "Nachweis einer aktivierenden Mutation BRAF V600E. Triple-Therapie mit einem EGFR-Antikörper sowie einem BRAF- und einem MEK- Inhibitor prüfen."
    },
    {
      "code": {
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "51963-7",
            "display": "Medication assessed [ID]"
          }
        ]
      },
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "http://www.whocc.no/atc",
            "code": "L01EC",
            "display": "B-Raf serine-threonine kinase (BRAF) inhibitors"
          },
          {
            "system": "http://snomed.info/sct",
            "code": "703645005",
            "display": "Product containing B-Raf inhibitor (product)"
          }
        ],
        "text": "BRAF Inhibitor"
      }
    },
    {
      "code": {
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "51963-7",
            "display": "Medication assessed [ID]"
          }
        ]
      },
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "http://www.whocc.no/atc",
            "code": "L01FE",
            "display": "EGFR (Epidermal Growth Factor Receptor) inhibitors"
          }
        ]
      }
    },
    {
      "code": {
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "51963-7",
            "display": "Medication assessed [ID]"
          }
        ]
      },
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "http://www.whocc.no/atc",
            "code": "L01EE",
            "display": "Mitogen-activated protein kinase (MEK) inhibitors"
          }
        ]
      }
    }
  ]
}